EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors also discussed that inactive EBNA3A and C alleles may permit EBV infected B cells to differentiate further into plasmablasts and fully differentiated functional plasma cells, eventually, solely upon silencing of p16INK4a.”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [17]
In the citing paper
“Both viral proteins have been implicated in blocking B cell differentiation towards plasmablasts and plasma cells [17], because they can act as epigenetic repressors of several cellular loci other than CDKN2A such as CDKN2C and PRDM1, which encode p18INK4c and BLIMP-1, respectively, and thus prevent terminal differentiation of lymphoblastoid B cells [17].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [17]
In the citing paper
“A seminal paper by the Allday laboratory reported that EBV-infected lymphoblastoid B cells differentiated spontaneously and acquired a plasma cell-like phenotype in the absence of EBNA3A and C using conditional EBNA3 alleles [17].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [17]
In the citing paper
“In a counterexample, our experiments did not recapitulate the function of two viral transcriptional repressors, EBNA3A and EBNA3C, which were reported to block terminal differentiation of mature B cells into plasmablasts or plasma cells [17].”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [17]
In the citing paper
“It implies that CDKN2A indirectly precludes the differentiation of cycling pre-plasmablasts [17]”
From Highly efficient CRISPR-Cas9-mediated gene knockout in primary human B cells for functional genetic studies of Epstein-Barr virus infection (2021) · cites this paper as [17]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 9×
“These data, and those described in many other reports, are consistent with EBNA3A and EBNA3C binding to regulatory elements, followed by the removal of activation-associated histone marks (e.g., H3/H4KAc), concomitant chromosomal conformational changes, and finally further covalent histone modifications by polycomb pr…”
BackgroundInfluentialEZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786 · cited 9×
“These data, and those described in many other reports, are consistent with EBNA3A and EBNA3C binding to regulatory elements, followed by the removal of activation-associated histone marks (e.g., H3/H4KAc), concomitant chromosomal conformational changes, and finally further covalent histone modifications by polycomb pr…”
MethodInfluential
Research works printed but not linked: 60
- JL Kutok, 2006, Spectrum of Epstein-Barr virus-associated diseases, Annu Rev Pathol, 1, 375, 10.1146/annurev.pathol.1.110304.100209 · DOI · Paper page
- LS Young, 2004, Epstein-Barr virus: 40 years on, Nat Rev Cancer, 4, 757, 10.1038/nrc1452 · DOI · Paper page
- LS Young, 2016, Epstein-Barr virus: more than 50 years old and still providing surprises, Nat Rev Cancer, 16, 789, 10.1038/nrc.2016.92 · DOI · Paper page
- E Forte, 2011, The role of microRNAs in Epstein-Barr virus latency and lytic reactivation, Microbes Infect, 13, 1156, 10.1016/j.micinf.2011.07.007 · DOI
- JE Roughan, 2009, The intersection of Epstein-Barr virus with the germinal center, J Virol, 83, 3968, 10.1128/JVI.02609-08 · doi:10.1128/jvi.02609-08
- DA Thorley-Lawson, 2013, The pathogenesis of Epstein-Barr virus persistent infection, Curr Opin Virol, 3, 227, 10.1016/j.coviro.2013.04.005 · DOI · Paper page
- F Heuts, 2014, T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice, J Virol, 88, 3235, 10.1128/JVI.02885-13 · DOI
- N Nagy, 2012, Soluble factors produced by activated CD4+ T cells modulate EBV latency, Proc Natl Acad Sci U S A, 109, 1512, 10.1073/pnas.1120587109 · doi:10.1073/pnas.1120587109
- LL Laichalk, 2005, Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo, J Virol, 79, 1296, 10.1128/JVI.79.2.1296-1307.2005 · DOI · Paper page
- MJ Allday, 2015, The EBNA3 family: Two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells, Curr Top Microbiol Immunol, 391, 61
- RE White, 2010, Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification, PLoS ONE, 5, e13979, 10.1371/journal.pone.0013979 · DOI
- JS Kalchschmidt, 2016, EBNA3C directs recruitment of RBPJ (CBF1) to chromatin during the process of gene repression in EBV infected B cells, PLoS Pathog, 12, e1005383, 10.1371/journal.ppat.1005383 · DOI
- S Jiang, 2014, Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4 composite sites and recruits Sin3A to repress CDKN2A, Proc Natl Acad Sci U S A, 111, 421, 10.1073/pnas.1321704111 · DOI
- SC Schmidt, 2015, Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes, Proc Natl Acad Sci U S A, 112, 554, 10.1073/pnas.1422580112 · DOI
- K Paschos, 2016, Core binding factor (CBF) is required for Epstein-Barr virus EBNA3 proteins to regulate target gene expression, Nucleic Acids Res
- MJ McClellan, 2013, Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming, PLoS Pathog, 9, e1003636, 10.1371/journal.ppat.1003636 · DOI
- JS Kalchschmidt, 2016, Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells, J Exp Med, 213, 921, 10.1084/jem.20160120 · DOI
- CD Wood, 2016, MYC activation and BCL2L11 silencing by a tumour virus through the large-scale reconfiguration of enhancer-promoter hubs, Elife, 5
- Q Bazot, 2015, Epstein-Barr virus proteins EBNA3A and EBNA3C together induce expression of the oncogenic microRNA cluster miR-221/miR-222 and ablate expression of its target p57KIP2, PLoS Pathog, 11, e1005031, 10.1371/journal.ppat.1005031 · DOI
- MJ Allday, 2013, EBV finds a polycomb-mediated, epigenetic solution to the problem of oncogenic stress responses triggered by infection, Front Genet, 4, 212, 10.3389/fgene.2013.00212 · DOI
- Q Bazot, 2014, Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B transcription via interaction with MIZ-1, Nucleic Acids Res, 42, 9700, 10.1093/nar/gku697 · DOI
- RE White, 2012, EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors, J Clin Invest, 122, 1487, 10.1172/JCI58092 · DOI · Paper page
- S Gagrica, 2012, Contrasting behavior of the p18INK4c and p16INK4a tumor suppressors in both replicative and oncogene-induced senescence, Cancer Res, 72, 165, 10.1158/0008-5472.CAN-11-2552 · DOI
- MR Tourigny, 2002, CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells, Immunity, 17, 179, 10.1016/S1074-7613(02)00364-3 · DOI
- L Morse, 1997, Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6, Immunity, 6, 47, 10.1016/S1074-7613(00)80241-1 · DOI · Paper page
- J O'Nions, 2004, Proliferation and differentiation in isogenic populations of peripheral B cells activated by Epstein-Barr virus or T cell-derived mitogens, J Gen Virol, 85, 881, 10.1099/vir.0.19704-0 · DOI
- CC Goodnow, 2010, Control systems and decision making for antibody production, Nat Immunol, 11, 681, 10.1038/ni.1900 · DOI · Paper page
- W Shi, 2015, Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells, Nat Immunol, 16, 663, 10.1038/ni.3154 · DOI · Paper page
- SL Nutt, 2015, The generation of antibody-secreting plasma cells, Nat Rev Immunol, 15, 160, 10.1038/nri3795 · DOI · Paper page
- M Minnich, 2016, Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation, Nat Immunol, 17, 331, 10.1038/ni.3349 · DOI · Paper page
- YH Yu, 2016, Factors that regulate the generation of antibody-secreting plasma cells, Adv Immunol, 131, 61, 10.1016/bs.ai.2016.03.001 · DOI
- K Igarashi, 2016, Orchestration of B lymphoid cells and their inner myeloid by Bach, Curr Opin Immunol, 39, 136, 10.1016/j.coi.2016.01.012 · DOI
- A Wang, 2015, Epstein-Barr virus nuclear antigen 3 (EBNA3) proteins regulate EBNA2 binding to distinct RBPJ genomic sites, J Virol, 90, 2906, 10.1128/JVI.02737-15 · DOI
- S Nam, 2016, Essential role of interferon regulatory factor 4 (IRF4) in immune cell development, Arch Pharm Res, 39, 1548, 10.1007/s12272-016-0854-1 · DOI
- R Feil, 1997, Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochem Biophys Res Commun, 237, 752, 10.1006/bbrc.1997.7124 · DOI · Paper page
- B Chambraud, 1990, Several regions of human estrogen receptor are involved in the formation of receptor-heat shock protein 90 complexes, J Biol Chem, 265, 20686, 10.1016/S0021-9258(17)30558-6 · DOI · Paper page
- S Maruo, 2006, Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells, Proc Natl Acad Sci U S A, 103, 19500, 10.1073/pnas.0604919104 · DOI · Paper page
- L Skalska, 2010, Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP, PLoS Pathog, 6, e1000951, 10.1371/journal.ppat.1000951 · DOI · Paper page
- L Skalska, 2013, Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines, PLoS Pathog, 9, e1003187, 10.1371/journal.ppat.1003187 · DOI · Paper page
- S Maruo, 2011, Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression, Proc Natl Acad Sci U S A, 108, 1919, 10.1073/pnas.1019599108 · DOI
- K Paschos, 2012, BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV, Nucleic Acids Res, 40, 7233, 10.1093/nar/gks391 · DOI
- K Nilsson, 1970, Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient, Clin Exp Immunol, 7, 477
- M Hallek, 1998, Multiple myeloma: increasing evidence for a multistep transformation process, Blood, 91, 3, 10.1182/blood.V91.1.3 · DOI · Paper page
- H Schmidlin, 2008, Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression, Blood, 112, 1804, 10.1182/blood-2008-01-136440 · DOI · Paper page
- E Cubedo, 2011, PRDM1/Blimp1 downregulates expression of germinal center genes LMO2 and HGAL, FEBS J, 278, 3065, 10.1111/j.1742-4658.2011.08227.x · doi:10.1111/j.1742-4658.2011.08227.x
- AC Rawstron, 2006, Immunophenotyping of plasma cells, Curr Protoc Cytom, 23
- N Robillard, 2014, Immunophenotype of normal and myelomatous plasma-cell subsets, Front Immunol, 5, 137, 10.3389/fimmu.2014.00137 · DOI · Paper page
- HT Maecker, 2012, Standardizing immunophenotyping for the Human Immunology Project, Nat Rev Immunol, 12, 191, 10.1038/nri3158 · DOI · Paper page
- EK Deenick, 2013, Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells, J Exp Med, 210, 2739, 10.1084/jem.20130323 · DOI · Paper page
- S Ikeyama, 1986, Purification and characterization of IgE produced by human myeloma cell line, U266, Mol Immunol, 23, 159, 10.1016/0161-5890(86)90038-6 · doi:10.1016/0161-5890(86)90038-6
- PA Nikitin, 2010, An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells, Cell Host Microbe, 8, 510, 10.1016/j.chom.2010.11.004 · DOI · Paper page
- B Zhao, 2011, Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth, Proc Natl Acad Sci U S A, 108, 14902, 10.1073/pnas.1108892108 · DOI · Paper page
- H Zhou, 2015, Epstein-Barr virus oncoprotein super-enhancers control B cell growth, Cell Host Microbe, 17, 205, 10.1016/j.chom.2014.12.013 · DOI · Paper page
- J Mandelbaum, 2010, BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma, Cancer Cell, 18, 568, 10.1016/j.ccr.2010.10.030 · DOI · Paper page
- M Boi, 2015, PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas, Leuk Lymphoma, 56, 1223, 10.3109/10428194.2014.953155 · DOI
- S Liu, 2016, Gata3 restrains B cell proliferation and cooperates with p18INK4c to repress B cell lymphomagenesis, Oncotarget, 7, 64007, 10.18632/oncotarget.11746 · DOI
- Y Xia, 2016, Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma, Leukemia
- ML Harth-Hertle, 2013, Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9, PLoS Pathog, 9, e1003638, 10.1371/journal.ppat.1003638 · DOI
- JA Reusch, 2015, Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters, J Virol, 89, 1731, 10.1128/JVI.02781-14 · DOI
- RE White, 2003, Generation and precise modification of a herpesvirus saimiri bacterial artificial chromosome demonstrates that the terminal repeats are required for both virus production and episomal persistence, J Gen Virol, 84, 3393, 10.1099/vir.0.19387-0 · doi:10.1099/vir.0.19387-0
Cited by
Epstein-Barr virus: Biology and clinical disease
Damania, B., Kenney, S. C., & Raab-Traub, N. (2022) · Cell · doi:10.1016/j.cell.2022.08.026 · Cited by 612
Farrell, P. J. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013023 · Cited by 541
Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
Münz, C. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0249-7 · Cited by 469
Akidil, E., Albanese, M., Buschle, A., Ruhle, A., Pich, D., Keppler, O. T., & Hammerschmidt, W. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009117 · Cited by 31
Metadata
- Authors
- Styles, C. T., Bazot, Q., Parker, G. A., White, R. E., Paschos, K., & Allday, M. J.
- ORCID
- Allday, Martin J.
- Venue
- PLOS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-08-03
- Volume
- 15
- Issue
- 8
- Pages
- e2001992
- ISSN
- 1545-7885
- Cited by
- 78
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.